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donor cells in blood vessels throughout the heart (63% of total cells
enumerated). Rarer donor cells were also found through the myo-
cardium in cells with patterns exhibiting the cross-striations of
striated muscle. Donor cells stained positive for Troponin I-C
(speciﬁc for cardiac muscle Troponin I) and for myosin heavy
chain (1-2 cells per 10-20 high power ﬁelds). Conclusion: We
documented engraftment and differentiation of donor UCB cells
into cardiac myocytes in a child transplanted for MPS III. It is
possible that donor cells may selectively homed to damaged myo-
cardium and subsequently differentiated in situ. After engraftment,
differentiation into myocardial cells may improve cardiac function
and subsequently diminish the likelihood of progressive heart fail-
ure with its attendant morbidity and mortality in patients with
MPS syndromes.
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LOWER POST-TRANSPLANT SERUM ALBUMIN LEVELS PREDICT SIG-
NIFICANTLY POORER SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Pedicano, J., Verma, A., Tomblyn, M., Gordon, L., Singhal, S., Tall-
man, M., Williams, S., Winter, J., Mehta, J. Northwestern University,
Chicago
Low serum albumin is a non-speciﬁc but powerful indicator of
poorer outcome in elderly and hospitalized patients, after surgery,
and in several other circumstances including on routine testing
(Goldwasser Feldman, J Clin Epidemiol 1997;50:693-703). Based
upon the observation that patients with signiﬁcant complications
after transplantation usually have lower albumin levels and those
with higher albumin levels are usually well, we analyzed the rela-
tionship between post-transplant albumin levels and overall sur-
vival in recipients of non-myeloablative allogeneic transplantation
(NMAT). Overall survival (OS) was chosen as an endpoint rather
than disease-free survival because a number of patients relapsing
after NMAT attain remission again and survive long-term, and a
higher albumin level after relapse may be a predictor of better
outcome too. 47 consecutive NMAT recipients with hematologic
malignancies (27-66 years; median 51) were studied. The condi-
tioning regimen was 100 mg/m2 melphalan on day -1 ( 50 mg/kg
cyclophosphamide on day -2 if no prior autograft), cyclosporine
(HLA-matched sibling donor; n  32) or tacrolimus (1-locus
mismatched sibling donor; n 3, or unrelated donor; n 12), and
mycophenolate mofetil. Albumin levels on days 0, 30, 60 and 90,
and average albumin levels over weeks 1-2, 3-4, 5-6, 7-8, 9-10,
11-12, and 13-16 were analyzed. All comparisons were for 3 vs
3 g/dL except weeks 1-2 and 3-4 where a 2.5 vs 2.5 g/dL
cut-off was used because most patients had relatively low albumin
levels for the ﬁrst month. In each of the 11 comparisons, the group
with the lower albumin level had a lower probability of OS at 18
months. The table shows the OS differences were statistically
signiﬁcant. This analysis conﬁrms our clinical impression of the
poor prognostic implication of low albumin levels after allogeneic
transplantation. Further work is required to explore how the out-
come of patients with low albumin can be improved by modifying
medical management.
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TEMPO OF NEUTROPHIL RECOVERY AND THE DEFINITION OF MY-
ELOID ENGRAFTMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT) IN PATIENTS NOT RECEIVING
GROWTH FACTORS POST-TRANSPLANT
Naik, P., Verma, A., Pedicano, J., Gordon, L., Singhal, S., Tallman,
M., Williams, S., Winter, J., Mehta, J. Northwestern University,
Chicago
Time to myeloid recovery after HSCT is usually deﬁned as the
ﬁrst of 3 consecutive days with an absolute neutrophil count (ANC)
of 0.5 109/L. HSCT registries and FACT require ANC0.5 for
3 days as adequate evidence of engraftment. The ﬁrst day with
ANC 0.5 can be considered the day of engraftment in autograft
recipients (Bone Marrow Transplant 2002;30:749-752). We have
shown this in 78 allograft recipients too (Rihn et al. ASH 2002).
However, the allograft study was limited by the fact that most
patients had received G-CSF post-transplant, and the stem cell
source was not uniform. We have now studied 49 patients al-
lografted using blood stem cells who did not receive post-trans-
plant G-CSF to see if the tempo of myeloid recovery was sustained.
The conditioning regimen, 100 mg/m2 melphalan ( 50 mg/kg
cyclophosphamide if no prior autograft), induced severe neutrope-
nia (ANC 0.1) in all patients. The CD34 cell dose was 1.4-
11.8  106/kg (median 5.0). The time to ANC 0.5 was 10-23
days (median 13). Potentially acceptable evidence of engraftment,
ANC on the 2 days following an initial value of 0.5, was available
in 46 (94%). The remaining 3 patients had ANC 0.5 for the ﬁrst
and second days but died after that (n  2) or did not have a
differential count available (n  1). ANC increased from day 1 to
2 in 41 of 46 patients, and declined in 5 (0.5 in 2, 0.5 in 3. 2 of
the latter had ANC 0.5 the next day). ANC increased from day
2 to 3 in 44 of 46 patients, and declined in 2 (0.5 in both). ANC
increased from day 1 to 3 in 45 of 46 patients; declining below 0.5
in 1 patient. Thus, in 43 of 46 patients, the ﬁrst day with ANC 0.5
was also the ﬁrst of 3 consecutive days with ANC 0.5. These data
support our previous observations that in the majority of al-
lografted patients, ANC does not decline signiﬁcantly immediately
after recovering to0.5 whether or not myeloid growth factors are
administered post-transplant. Therefore, it is not essential to ob-
tain WBC counts on 3 consecutive days to deﬁne myeloid engraft-
ment. The ﬁrst day with ANC 0.5 should be considered the day
of myeloid engraftment in allograft as well as autograft recipients.
This simple change in deﬁnition and practice has signiﬁcant po-
tential impact on convenience (unnecessary clinic visits for pa-
tients; particularly out-patient mini-allografts), cost (blood counts,
home health visits, ancillary charges), and compliance (acceptable
deﬁnition of engraftment by HSCT registries and FACT).
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INTERACTION BETWEEN DONOR TYPE AND CMV SEROSTATUS ON
MORTALITY AFTER ALLOGENEIC HSCT: DO PREEMPTIVE APPROACHES
WORK EQUALLY FOR ALL?
Nichols, W.G., Gooley, T.A., Boeckh, M. Fred Hutchinson Cancer
Research Center, Seattle, WA
Background: In the current era of effective preemptive antiviral
approaches, cytomegalovirus (CMV) is now a rare cause of early
mortality after hematopoietic stem cell transplantation (HSCT).
Though the direct effects of CMV (such as CMV pneumonia) have
been largely eliminated, many recent cohort studies (reviewed in
Table.
Time
Higher Albumin Lower Albumin
Pn 1-y OS (95% CI) (%) n 1-y OS (95% CI) (%)
Day 60 25 73 (51-94) 13 48 (19-78) 0.01
Weeks 1-2 24 75 (56-94) 23 20 (0-51) 0.01
Weeks 3-4 24 76 (56-97) 22 35 (9-61) 0.01
Weeks 5-6 27 69 (48-90) 17 42 (17-67) 0.02
Weeks 7-8 24 78 (58-97) 14 33 (5-62) 0.003
Weeks 9-10 24 74 (54-94) 11 47 (14-79) 0.05
Table.
Day 1 Day 2 Day 3
ANC (109/L) 0.74 (0.53-2.10) 1.43 (0.36-10.94) 2.46 (0.44-30.74)
Change from
Day 1 (%) 67 (36 to 574) 176 (21 to 1793)
Change from
Day 2 (%) 50 (17 to 1925)
ANC <0.5
(n) 0 3 (7%) 1 (2%)
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